The prognostic implications from molecular testing of thyroid cancer.
Thyroid cancer is the most common endocrine malignancy and its incidence has increased over the past few decades. Most patients with thyroid cancer have an excellent prognosis, but there is a 15% recurrence rate within 10 years after initial treatment and mortality is possible. To date, there are no prospective, well-defined data supporting the use of molecular markers alone to decide the extent of treatment of patients with thyroid cancer or to predict the individual prognosis of these patients. Molecular markers are promising in the development of new targeted therapies particularly for radioiodine-refractory and unresectable thyroid cancers.